Nexgel Inc(NXGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:14 PM ET (Korea 11/7 06:14)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -14.35 | Insider Own | 14.08% | Shs Outstand | 0.5M | Perf Week | 2.56% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 76.6% | Insider Trans | -7.49% | Shs Float | 0.4M | Perf Month | 20% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -4.8 | Inst Own | 6.23% | Short Float | 24.94% | Perf Quarter | -50.33% |
| Income | -0.01B | P/S | 0.92 | EPS this Y | -147.37% | Inst Trans | - | Short Ratio | 0.94 | Perf Half Y | -69.66% |
| Sales | 0.01B | P/B | 0.35 | EPS next 5Y | 49.14% | ROA | -34.21% | Short Interest | 0.10M | Perf YTD | -88.82% |
| Book/sh | 10.2 | P/C | 6.47 | EPS past 3/5Y | 23.45% -77.45% | ROE | -128.59% | 52W High | -93.28% ($53.60) | Perf Year | -92.47% |
| Cash/sh | 0.56 | P/FCF | - | Sales past 3/5Y | 77.33% 76.12% | ROIC | -53.83% | 52W Low | 20% ($3.00) | Perf 3Y | -90.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -78.48% | Gross Margin | 34.73% | Volatility(W/M) | 15.25% 21.47% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.44 | Sales Y/Y TTM | 3.38% | Oper. Margin | -44.77% | ATR (14) | 0.71 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.27 | EPS Q/Q | -364.19% | Profit Margin | -51.26% | RSI (14) | 41.85 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.43 | Sales Q/Q | 27.81% | SMA20 | -19.93% ($4.5) | Beta | 0.73 | Target Price | $40 |
| Payout | - | Debt/Eq | 1.51 | Earnings | 2026/8/14 | SMA50 | -25.46% ($4.83) | Rel Volume | 0.12 | Prev Close | $4.12 |
| Employees | 19 | LT Debt/Eq | 1.32 | EPS/Sales Surpr. | -233.33% -14.58% | SMA200 | -69.55% ($11.82) | Avg Volume(3M) | 0.11M | Price | $3.6 |
| IPO | 2021/12/22 | Option/Short | No/Yes | Trades | 540 | Volume | 13,884 | Change | -12.57% |
🩹 NexGel (NXGL) is a U.S. micro-cap medical device and consumer healthcare company that manufactures high-performance hydrogels using proprietary electron beam technology. It operates both its own branded OTC products and contract manufacturing, and is currently expanding into the regenerative medicine field through its recent acquisition of Celularity assets.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 12% of its average volume.
NXGL has weak earnings and a weak balance sheet
Of every $100 in sales, $44.77 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -147.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $92. Peers typically go for $254.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -90.4%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
24.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #48 of 51 in the industry
Based on market cap of $11M.
FAQ
What kind of company is NXGL?
NXGL belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of NXGL?
The market cap of NXGL is approximately $11M, ranking 5,387 within its sector.
What is the 52-week high and low for NXGL?
NXGL has recorded a 52-week high of $53.60 and a low of $3.00.
